• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Neither Surgical Margin Status nor Somatic Mutation Predicts Local Recurrence After R0-intent Resection for Colorectal Liver Metastases.无论切缘状态还是体突变都不能预测结直肠肝转移 R0 切除术后局部复发。
J Gastrointest Surg. 2022 Apr;26(4):791-801. doi: 10.1007/s11605-021-05173-0. Epub 2021 Nov 1.
2
RAS Mutation Predicts Positive Resection Margins and Narrower Resection Margins in Patients Undergoing Resection of Colorectal Liver Metastases.RAS突变可预测接受结直肠癌肝转移灶切除患者的切缘阳性及切缘较窄情况。
Ann Surg Oncol. 2016 Aug;23(8):2635-43. doi: 10.1245/s10434-016-5187-2. Epub 2016 Mar 25.
3
Effect of Co-mutation of RAS and TP53 on Postoperative ctDNA Detection and Early Recurrence after Hepatectomy for Colorectal Liver Metastases.RAS与TP53共突变对结直肠癌肝转移肝切除术后循环肿瘤DNA检测及早期复发的影响
J Am Coll Surg. 2022 Apr 1;234(4):474-483. doi: 10.1097/XCS.0000000000000093.
4
Does KRAS mutation status impact the risk of local recurrence after R1 vascular resection for colorectal liver metastasis? An observational cohort study.KRAS 基因突变状态是否会影响结直肠肝转移行 R1 血管切除术后局部复发的风险?一项观察性队列研究。
Eur J Surg Oncol. 2020 May;46(5):818-824. doi: 10.1016/j.ejso.2019.12.004. Epub 2019 Dec 5.
5
Recurrence at surgical margin following hepatectomy for colorectal liver metastases is not associated with R1 resection and does not impact survival.结直肠肝转移瘤行肝切除术后手术切缘复发与 R1 切除无关,且不影响生存。
Surgery. 2021 May;169(5):1061-1068. doi: 10.1016/j.surg.2020.11.024. Epub 2020 Dec 30.
6
RAS Mutation is Associated with Unsalvageable Recurrence Following Hepatectomy for Colorectal Cancer Liver Metastases.RAS 突变与结直肠癌肝转移切除术后无法挽救的复发相关。
Ann Surg Oncol. 2018 Aug;25(8):2457-2466. doi: 10.1245/s10434-018-6517-3. Epub 2018 May 21.
7
Conditional Recurrence-Free Survival after Resection of Colorectal Liver Metastases: Persistent Deleterious Association with RAS and TP53 Co-Mutation.结直肠肝转移切除后的无复发生存条件:RAS 和 TP53 共突变持续存在有害关联。
J Am Coll Surg. 2019 Sep;229(3):286-294.e1. doi: 10.1016/j.jamcollsurg.2019.04.027. Epub 2019 May 2.
8
SMAD4 gene mutation predicts poor prognosis in patients undergoing resection for colorectal liver metastases.SMAD4 基因突变预测结直肠肝转移患者切除术后预后不良。
Eur J Surg Oncol. 2018 May;44(5):684-692. doi: 10.1016/j.ejso.2018.02.247. Epub 2018 Mar 7.
9
Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases.手术切缘状态对结直肠癌肝转移灶切除术后生存及复发部位的影响。
Ann Surg. 2005 May;241(5):715-22, discussion 722-4. doi: 10.1097/01.sla.0000160703.75808.7d.
10
RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases.RAS 基因突变状态可预测行肝切除术的结直肠癌肝转移患者的生存和复发模式。
Ann Surg. 2013 Oct;258(4):619-26; discussion 626-7. doi: 10.1097/SLA.0b013e3182a5025a.

引用本文的文献

1
A Randomized Controlled Trial of Resection Versus Thermal Ablation of Colorectal Cancer Liver Metastases (New Comet): Study Protocol.一项关于结直肠癌肝转移灶切除与热消融治疗的随机对照试验(新彗星研究):研究方案
Ann Surg Oncol. 2025 Aug 26. doi: 10.1245/s10434-025-17984-5.
2
CEA Rebound After Discontinuation of Pre-Hepatectomy Chemotherapy Predicts Worse Outcomes After Resection of Colorectal Cancer Liver Metastases.肝切除术前化疗停药后癌胚抗原(CEA)反弹预示着结直肠癌肝转移切除术后预后更差。
Ann Surg Oncol. 2025 Feb;32(2):1021-1032. doi: 10.1245/s10434-024-16370-x. Epub 2024 Nov 8.
3
A critical appraisal of the current landscape of resectable BRAF mutated colorectal liver metastases: a systematic review.可切除 BRAF 突变结直肠癌肝转移现状的批判性评价:系统综述。
Chin Clin Oncol. 2024 Aug;13(4):51. doi: 10.21037/cco-23-128. Epub 2024 May 28.
4
Optimizing Treatment Strategy for Oligometastases/Oligo-Recurrence of Colorectal Cancer.优化结直肠癌寡转移/寡复发的治疗策略
Cancers (Basel). 2023 Dec 27;16(1):142. doi: 10.3390/cancers16010142.
5
Locoregional treatment for colorectal liver metastases aiming for precision medicine.以精准医学为目标的结直肠癌肝转移的局部区域治疗。
Ann Gastroenterol Surg. 2023 May 18;7(4):543-552. doi: 10.1002/ags3.12689. eCollection 2023 Jul.
6
Hepatectomy Before Primary Tumor Resection as Preferred Approach for Synchronous Liver Metastases from Rectal Cancer.肝切除术在原发肿瘤切除前作为直肠癌同步肝转移的首选方法。
Ann Surg Oncol. 2023 Sep;30(9):5390-5400. doi: 10.1245/s10434-023-13656-4. Epub 2023 Jun 7.
7
Precision Surgery of Colorectal Liver Metastases in the Current Era: A Systematic Review.当代结直肠癌肝转移的精准手术:一项系统评价
Cancers (Basel). 2023 Mar 31;15(7):2083. doi: 10.3390/cancers15072083.
8
Artificial Intelligence or Tumor Biology to Predict Survival After Resection of Colorectal Liver Metastases?人工智能还是肿瘤生物学能预测结直肠癌肝转移切除术后的生存率?
Ann Surg Oncol. 2023 Jun;30(6):3161-3162. doi: 10.1245/s10434-023-13223-x. Epub 2023 Feb 21.
9
Survival improvement for patients with metastatic colorectal cancer over twenty years.二十年来转移性结直肠癌患者的生存改善情况。
NPJ Precis Oncol. 2023 Feb 13;7(1):16. doi: 10.1038/s41698-023-00353-4.
10
Histopathological Growth Pattern in Colorectal Liver Metastasis and The Tumor Immune Microenvironment.结直肠癌肝转移的组织病理学生长模式与肿瘤免疫微环境
Cancers (Basel). 2022 Dec 28;15(1):181. doi: 10.3390/cancers15010181.

本文引用的文献

1
Improved Survival over Time After Resection of Colorectal Liver Metastases and Clinical Impact of Multigene Alteration Testing in Patients with Metastatic Colorectal Cancer.结直肠癌肝转移切除术后随时间推移生存率的改善以及多基因改变检测对转移性结直肠癌患者的临床影响
J Gastrointest Surg. 2022 Mar;26(3):583-593. doi: 10.1007/s11605-021-05110-1. Epub 2021 Sep 10.
2
Recurrence at surgical margin following hepatectomy for colorectal liver metastases is not associated with R1 resection and does not impact survival.结直肠肝转移瘤行肝切除术后手术切缘复发与 R1 切除无关,且不影响生存。
Surgery. 2021 May;169(5):1061-1068. doi: 10.1016/j.surg.2020.11.024. Epub 2020 Dec 30.
3
Alteration of FBXW7 is Associated with Worse Survival in Patients Undergoing Resection of Colorectal Liver Metastases.FBXW7 改变与结直肠癌肝转移切除术后患者的生存预后不良相关。
J Gastrointest Surg. 2021 Jan;25(1):186-194. doi: 10.1007/s11605-020-04866-2. Epub 2020 Nov 17.
4
Nicaraven Attenuates Postoperative Systemic Inflammatory Responses-Induced Tumor Metastasis.尼卡巴嗪减轻术后全身炎症反应诱导的肿瘤转移。
Ann Surg Oncol. 2020 Apr;27(4):1068-1074. doi: 10.1245/s10434-019-08076-2. Epub 2019 Dec 23.
5
KRAS Mutation Predicted More Mirometastases and Closer Resection Margins in Patients with Colorectal Cancer Liver Metastases.KRAS 突变预测结直肠癌肝转移患者存在更多的微小转移灶和更接近的切缘。
Ann Surg Oncol. 2020 Apr;27(4):1164-1173. doi: 10.1245/s10434-019-08065-5. Epub 2019 Nov 12.
6
Coaltered and Is Associated with Extremes of Survivorship and Distinct Patterns of Metastasis in Patients with Metastatic Colorectal Cancer.在转移性结直肠癌患者中,Coaltered 与生存极限和转移的独特模式相关。
Clin Cancer Res. 2020 Mar 1;26(5):1077-1085. doi: 10.1158/1078-0432.CCR-19-2390. Epub 2019 Nov 12.
7
Extended Molecular Profiling Improves Stratification and Prediction of Survival After Resection of Colorectal Liver Metastases.扩展分子谱分析可改善结直肠癌肝转移切除术后的分层和生存预测。
Ann Surg. 2019 Nov;270(5):799-805. doi: 10.1097/SLA.0000000000003527.
8
Mutation Status of , and is Superior to Mutation Status of Alone for Predicting Prognosis after Resection of Colorectal Liver Metastases.对于结直肠癌肝转移切除术后的预后, 突变状态优于 突变状态。
Clin Cancer Res. 2019 Oct 1;25(19):5843-5851. doi: 10.1158/1078-0432.CCR-19-0863. Epub 2019 Jun 20.
9
Conditional Recurrence-Free Survival after Resection of Colorectal Liver Metastases: Persistent Deleterious Association with RAS and TP53 Co-Mutation.结直肠肝转移切除后的无复发生存条件:RAS 和 TP53 共突变持续存在有害关联。
J Am Coll Surg. 2019 Sep;229(3):286-294.e1. doi: 10.1016/j.jamcollsurg.2019.04.027. Epub 2019 May 2.
10
Sub-millimeter surgical margin is acceptable in patients with good tumor biology after liver resection for colorectal liver metastases.肝切除治疗结直肠肝转移术后,对于肿瘤生物学特性良好的患者,亚毫米切缘是可以接受的。
Eur J Surg Oncol. 2019 Sep;45(9):1551-1558. doi: 10.1016/j.ejso.2019.03.010. Epub 2019 Mar 9.

无论切缘状态还是体突变都不能预测结直肠肝转移 R0 切除术后局部复发。

Neither Surgical Margin Status nor Somatic Mutation Predicts Local Recurrence After R0-intent Resection for Colorectal Liver Metastases.

机构信息

Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1484, Houston, TX, 77030, USA.

Hepato-Biliary-Pancreatic Surgery Division, Department of Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.

出版信息

J Gastrointest Surg. 2022 Apr;26(4):791-801. doi: 10.1007/s11605-021-05173-0. Epub 2021 Nov 1.

DOI:10.1007/s11605-021-05173-0
PMID:34725784
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11875739/
Abstract

BACKGROUND

We evaluated the associations of surgical margin status and somatic mutations with the incidence of local recurrence (LR) and oncologic outcomes in patients undergoing R0-intent (microscopically negative margin) resection of colorectal liver metastases (CLM).

METHODS

Patients with CLM who underwent initial R0-intent resection and analysis of tumor tissue using next-generation sequencing during 2001-2018 were analyzed. Recurrences were classified as LR (at the resection margin), other intrahepatic recurrence, or extrahepatic recurrence. Predictors and survival effect of LR were evaluated using univariate and multivariate analysis.

RESULTS

Of 552 patients analyzed, 415 (75%) had R0 resection (margin width ≥ 1.0 mm), and 38 (7%) had LR. LR incidence was not affected by surgical margin width. RAS/TP53 co-mutation was associated with increased risk of intrahepatic recurrence (67% vs. 49%; p < 0.001) and overall recurrence (p < 0.001). However, incidence of LR did not differ significantly by RAS/TP53, BRAF, SMAD4, or FBXW7 mutation. Extrahepatic disease (hazard ratio [HR], 1.47; p = 0.034), > 8 cycles of preoperative chemotherapy (HR, 1.98; p = 0.033), tumor viability ≥ 50% (HR, 1.55; p = 0.007), RAS/TP53 co-mutation (HR, 1.69; p = 0.001), and SMAD4 mutation (HR, 2.44; p < 0.001) were independently associated with poor overall survival, but surgical margin status was not.

CONCLUSIONS

Although somatic mutations were associated with overall recurrence, neither surgical margin width nor somatic mutations affected LR risk after R0-intent hepatectomy for CLM. LR and prognosis were likely driven by individual tumor biology rather than surgical margins.

摘要

背景

我们评估了手术切缘状态和体细胞突变与接受结直肠肝转移(CLM)R0 意向(显微镜下无肿瘤边缘)切除术患者局部复发(LR)和肿瘤学结果的相关性。

方法

分析了 2001 年至 2018 年间接受初始 R0 意向切除和使用下一代测序分析肿瘤组织的 CLM 患者。复发分为 LR(在切缘处)、其他肝内复发或肝外复发。使用单因素和多因素分析评估 LR 的预测因素和生存影响。

结果

在分析的 552 名患者中,415 名(75%)接受了 R0 切除术(切缘宽度≥1.0mm),38 名(7%)发生了 LR。LR 的发生率与手术切缘宽度无关。RAS/TP53 共突变与肝内复发(67%比 49%;p<0.001)和总复发(p<0.001)的风险增加相关。然而,LR 的发生率在 RAS/TP53、BRAF、SMAD4 或 FBXW7 突变方面没有显著差异。肝外疾病(危险比[HR],1.47;p=0.034)、>8 个周期的术前化疗(HR,1.98;p=0.033)、肿瘤活力≥50%(HR,1.55;p=0.007)、RAS/TP53 共突变(HR,1.69;p=0.001)和 SMAD4 突变(HR,2.44;p<0.001)与总生存不良独立相关,但手术切缘状态无关。

结论

尽管体细胞突变与总复发相关,但 R0 意向肝切除术后,手术切缘宽度和体细胞突变均不影响 LR 风险。LR 和预后可能受个体肿瘤生物学而不是手术切缘的驱动。